Clinical Trial Update: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study [Phase 4]

View source ↗

Summary

Phase 4 trial update on allowing access to nilotinib for patients already receiving nilotinib in a Novartis-sponsored study; study status completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Gastrointestinal Stromal Tumors

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 4 | Status: COMPLETED | Results posted: 2024-02-08